Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Wednesday 04 September, 2002

XTL Biopharm Ltd

XTL APPOINTS CHIEF MEDICAL OFFICER


XTL APPOINTS CHIEF MEDICAL OFFICER AND LAUNCHES SECOND US OFFICE

Rehovot, Israel, 4 September 2002 - XTL Biopharmaceuticals Ltd. (LSE: XTL)
announced today the appointment of Neil Graham, MD, as Chief Medical Officer.
Dr. Graham was formerly Vice President, Clinical Research and Medical Affairs
at Tibotec-Virco NV, a subsidiary of Johnson and Johnson Corporation (NYSE:
JNJ), involved in the development of treatments for HIV. Prior to that, Dr.
Graham worked at GlaxoWellcome Inc., now GlaxoSmithKline (NYSE: GSK), as
Director of HIV Programs in the US, where he helped design and implement
clinical trials for Combivir, Trizivir, Agenerase, Fosamprenavir, Ziagen and
Epivir QD. Dr. Graham and his staff will be working in the newly established
XTL office in Research Triangle Park, Durham, North Carolina.

'While at Tibotec, Dr. Graham created a world-class clinical team from scratch.
The US$320 million acquisition by J&J is attributable, in part, to his
excellent work,' stated Martin Becker, PhD, Chief Executive Officer of XTL.
'Neil adds an important dimension to the XTL management team and we look
forward to expanding the Company's presence into Research Triangle Park, a
centre for scientific research and discovery.'

Dr. Graham received his MD and Master of Public Health degrees from the
University of Adelaide in Australia. Dr. Graham held various research and
teaching posts at Johns Hopkins University Schools of Medicine and Hygiene and
Public Health, where he focused on HIV, TB and hepatitis epidemiology research.

ABOUT XTL

XTL Biopharmaceuticals Ltd. (LSE: XTL) is a leading drug development company
committed to combating the growing threat of Hepatitis B and C and other
infectious diseases. XTL's HepeX™ product line - now in clinical trials - has
the potential to introduce revolutionary Hepatitis therapies, including a
'cocktail' approach to chronic illness and treatment against re-infection of
transplanted livers. XTL believes its primary competitive advantage lies in its
patented Trimera™ technology, which enables the development of human monoclonal
antibodies and models of human disease for pre-clinical drug validation. For
more information, please visit www.xtlbio.com.

HepeX, Trimera and XTL are trademarks of XTL Biopharmaceuticals Ltd.

XTL CONTACTS

Ian Tick                          Mitchell Benus             
                                                             
Head of Corporate Communications  Director of Investor       
                                  Relations                  
                                                             
+972-8-930-4409                   +1-347-245-6408            
                                                             
itick@xtlbio.com                  mbenus@xtlbio.com